FDA Citations to Delay Indian Drugmaker Lupin’s U.S. Expansion

International Pharmaceutical Regulatory Monitor
A A
Indian drugmaker Lupin is facing delays in expanding its presence in the U.S. market after an FDA inspection uncovered deficiencies at a company facility.

To View This Article:

Login

Subscribe To International Pharmaceutical Regulatory Monitor